Yuva - India

Johnson and Johnson seeking permission in India

The global outbreak of the COVID-19 is rapidly spreading through the country leading to exigent demand of the vaccine. Earlier, the deteriorating graphs of the resuscitation from the critical phase.

However, the unforeseen rise in cases has given a rough idea that there might be still more time for the graph to reach its peak if a similar condition prevails. Both the cases and conditions about the current situation of COVID-19 have called for the high demand for vaccines at an accelerated rate.

Among the introduced vaccines like Johnson & Johnson, Pzifer, Moderna, covaxin, and covishield, only the two made-in-India vaccines are being allowed by the government of India, namely Covaxin and Covishield. Johnson & Johnson is currently known to undergo acceptance for its applications in India, for the phase three trial of its single dose.

For the bestowal of our country with the vaccine of Johnson & Johnson, the third trial conductance had to deal with an early meeting regarding the COVID-19 via subject expertise. The Central Drugs Standard Control Organization (CDSCO) is to decide for its single shot and also for importing its license.

Concerning the rising cases and therefore the seriousness of things, it had been an emergency involving the approval of the required vaccine in our country. Regarding the chances of appeal, two major facts hold alibis about the present situation. The first is granting the use of foreign products and remedies against the coronavirus by the World Health Organization in Britain, the United States, Japan, and Europe.

The up to the minute mutant of the virus had been more deadly, leading to a concerning phase of the increasing COVID-19 cases. The new mutant tends to affect even the youth and the kids unlike the case in last year where the threat was prone to the senior citizens and those possessing weak immunity.

Regarding Johnson &Johnson, the clinical trial on April twelve was done in the Global Clinic Trial Division. It was done via the Sugam Online portal. Apart from the two vaccines being administered in India, namely Covaxin by Bharat Biotech and Covishield by Serum Institute in India, a third one, Sputnik V is also supposed to be utilized after the approval of the Indian drug regulator. The vaccine developed by Russia is to be brought into use by Dr. Reddy’s laboratories according to the sources.

In the process of trial of being dispensable, Johnson & Johnson had also resubmitted its application on Monday. On a valid rationale, Johnson & Johnson had been compared to other vaccines currently being used in India. The storage capability of the vaccine is up to three months and the required temperature should be between two and eight degrees Celsius.

Where other vaccines comprise double doses, Johnson & Johnson only needs a single dose to be given. Johnson & Johnson had not yet applied to the biological division dealing with vaccines. Moreover, according to the surveys, this vaccine is supposed to cause severe blood clots among a small fraction of people. With effects similar to the AstraZeneca vaccine, and unique blood clot issues, the acceptance of Johnson & Johnson is still being questioned for trial three. Some sources have also resulted in a low platelet count after the receiving of Johnson & Johnson.

If we talk about AstraZeneca, a country like France had to struggle with the trade of Johnson & Johnson and hence making its use common despite the issues related to the blood clot. The Philippines had also already suspended the use of the vaccine for people aged above sixty. Now some of the sources still face perplexity regarding the relation of Johnson & Johnson with AstraZeneca while some claim both to be significantly dissimilar. This had caused to cease of the trial of Johnson & Johnson.

Indian population comprising of the youth in the majority, are supposed to be the future of our country. The realization of the necessity in the pace of the distribution of COVID-19 vaccines has also been leveraged to age groups above eighteen. They will be eligible for the COVID-19 vaccine from the first of May, this year.

However, the Johnson & Johnson vaccine was authorized by U.S. FDA for emergency use. Keeping in mind the various pros and cons of the Johnson & Johnson vaccine, the government of India is concerned regarding the amelioration of the present situation ensuring the safety and healthcare of the people leading to a liberalized as well as expedited strategy of COVID-19.

Supriya Rani

Intern, Goa Chronicle

DISCLAIMER: This article reflects author’s view point. Goa Chronicle may or may not subscribe to views of the author

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker